News >

Chao Discusses Impact of RAINBOW, TAGS, and KEYNOTE Trials in Gastric/GEJ Cancer

Caroline Seymour
Published: Tuesday, Feb 12, 2019

Joseph Chao, MD

Joseph Chao, MD

THE RAINBOW AND TAGS trials have demonstrated strong evidence to support the use of ramucirumab (Cyramza) and TAS-102 (trifluridine/tipiracil; Lonsurf) in patients with advanced gastric or gastroesophageal (GEJ) cancer who have progressed on first-line therapy. However, additional data suggest that with proper patient selection, immunotherapy will become equally as valuable to patients with progressive disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x